ALS Texas

  • Facebook
  • Instagram
  • Pinterest
  • Twitter
  • Newsletter
  • Find Services
  • Understanding ALS
    • ALS Symptoms
    • Stages of ALS
    • What Causes ALS?
    • Lou Gehrig and the History of ALS
    • ALS Glossary
  • Who We Are
    • What We Do
    • Our Leadership
    • Financial Information
    • Our Partners
    • Careers
  • Research
    • How ALS Patients Can Help
    • Research Resources
    • Research News
    • ALS Association Research
  • Navigating ALS
    • Newly Diagnosed
      • What Do I Do Now?
      • How to Share Your Diagnosis
      • Second Opinions
      • Resources
      • Clinics and Centers
    • Living with ALS
      • For Patients
      • Therapies & Care
        • Nutrition & Feeding Tubes
        • How to Improve Mobility
        • Dealing with Breathing Issues
        • Dealing with Speech & Swallowing Issues
        • Types of Assistive Equipment & Technology
        • Clinics and Centers
      • Living Setting
      • Daily Living Activities
      • Leisure Activities
      • Accessible Vehicles
      • More in Depth Resources/Manuals
    • Coping with ALS
      • Dealing with Anxiety/Depression
      • Changes in Thinking & Emotional Lability
      • Support Groups
      • Resources
    • For Caregivers
      • Caregiver Resources
      • Practicing Self Care
      • From One Caregiver To Another
    • For Youth & Children
    • Virtual Support Groups & Workshops
      • Past Virtual Event Recordings
    • Resources
      • Healthcare/Insurance
      • Hospice & Palliative Care
      • Finances/Employment
      • Taxes
      • Advance Directives
      • More in Depth Resources/Manuals
      • Register with ALS Texas
  • Contact Us
  • Donate
    • Ways to Donate to ALS Texas
    • Corporate Partnerships
    • Workplace Giving
    • Community Giving Programs
  • Advocate
    • Advocacy Day
    • Advocacy News
  • Get Involved
    • Walk to Defeat ALS®
      • Register for a Walk
    • Texas Chapter Events
      • Houston Marathon and Half Marathon
      • All In For ALS Poker Tournament
      • Sporting Clay Shoot
      • Under Ballou Skies Golf Classic and Party
      • ALS Fishing Classic
      • The Cowtown Affair
    • Fundraising Opportunities
    • Calendar of Events
    • Volunteer
    • The ALS Ice Bucket Challenge

The ALS Association Continues to Push Development of Novel Treatments

April 24, 2020 by Katie Kroncke Leave a Comment

The ALS Association is excited to announce $2.5 million in grants to help develop promising new treatments for people living with ALS.

The grants are supported by the Association’s Lawrence and Isabel Barnett Drug Development Program, which supports drug discovery research in both academia and industry to develop new drug therapies and test them in a preclinical setting while moving those therapies closer to clinical use.

“This program funds preclinical projects aimed at developing treatments for ALS,” said Kuldip Dave, Ph.D., vice president of research at The ALS Association. “We anticipate that the agents and data generated from these projects will lead to the advancement of new promising therapies for ALS.”

While we continue to add new projects to this portfolio, these latest grant awards are showing a great deal of promise and hope for people living with ALS.

INmuneBio was awarded $500,000 allocated over two years to support proof of concept testing of XPro1595 for use in ALS therapy. XPro1595 has advanced to clinical testing for Alzheimer’s disease, but its use in ALS is novel. It targets immune dysfunction and inflammation by blocking the development of bad soluble TNF, a cell-signaling protein. The principal investigator for the study is CJ Barnum, Ph.D., director of neuroscience at INmune Bio. For more information, click here.

Peter Crouch of the University of Melbourne was awarded $495,176 to support animal testing of the novel use of copper-ATSM combined with follistatin. The proof of concept testing builds on the theory that effective ALS treatment could require drug cocktails, or the combination of multiple drugs and will occur concurrently to clinical testing already underway to test the efficacy of copper ATSM more generally. The ALS Association Oregon and SW Washington Chapter contributed $300,000 to the project.

Neuropore Therapies, Inc. was awarded $500,000 in support of their preclinical evaluations of NPT1220-312, a small molecule Toll-Like 2 receptor (TLR2) antagonist, as a potential ALS treatment targeting inflammation and the immune system. Early work in the area of TLR2 antagonists has been promising. This research will provide key efficacy and translational biomarker data, which will be used to drive a go/no go decision to transition NPT1220-312 to clinical development as a disease-modifying ALS therapeutic. The principal investigator for the study is Diane Price. For more information, click here.

Bloom Science Inc. was awarded a $500,000 grant to explore preclinical development of a Live Biotherapeutic Product used in the treatment of ALS. Bloom is leveraging its GOLD platform (Genetically Optimized Living Drugs) in combination with strong preclinical data to advance a new generation of therapeutics aimed at managing microbiota, or the spectrum of bacteria that naturally populate the human gut. They propose that the gut microbiome plays an important role in metabolizing the diet to liberate factors that ultimately protect against neurological damage that contributes to ALS pathology. The principal investigator of the study is Christopher Reyes. For more information, click here.

ImmunoBrain Checkpoint was awarded $499,413 to further studies targeting immune-checkpoint pathways, another therapeutic approach for ALS. The immune system, beyond its immediate role in fighting pathogens, is involved in supporting brain function, in health and in disease. In neurodegenerative conditions, and specifically in ALS, immune system failure is characterized along with disease progression. Currently, in advance stages of developing this approach for Alzheimer’s disease, these studies aim to collect biomarkers of the evoked immune response following treatment, which they believe are key for clinical translation of the results. The principal investigator on the study is Kuti Baruch.

Click here to learn more about The Association’s research commitments and the many grants made possible by the kindness and generosity of donors to the Lawrence and Isabel Barnett Drug Development Program.

Original blog post was published here.

Filed Under: Research News

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Research News

Research News

How ALS Patients Can Help

How ALS Patients Can Help

Donate

Donate
  • Site Map
  • Privacy Policy
  • Link Policy
  • Contact Us

The ALS Association of Texas | 877.714.0088
All content and works posted on this website are owned and copyrighted by the ALS Association of Texas © 2019


Dallas Office 14555 Dallas Parkway Suite 100-219, Dallas, Texas 75254
San Antonio Office We're working from home! Please send mail to the Dallas office.
Austin Office 2301 W Anderson Lane, Austin, TX, 78757
Houston Office 1213 Hermann Drive, Suite 525, Houston, Texas 77004